CeriBell (NASDAQ:CBLL) Director William Burke Sells 2,207 Shares of Stock

CeriBell, Inc. (NASDAQ:CBLL) Director William Burke sold 2,207 shares of the company’s stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $19.84, for a total transaction of $43,786.88. Following the sale, the director directly owned 23,022 shares in the company, valued at $456,756.48. This represents a 8.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

CeriBell Price Performance

Shares of NASDAQ CBLL traded down $0.25 during mid-day trading on Thursday, hitting $19.75. 588,020 shares of the stock were exchanged, compared to its average volume of 328,686. CeriBell, Inc. has a twelve month low of $10.85 and a twelve month high of $24.33. The stock’s fifty day simple moving average is $18.84 and its two-hundred day simple moving average is $19.73. The company has a debt-to-equity ratio of 0.14, a quick ratio of 10.01 and a current ratio of 10.44. The company has a market cap of $749.34 million, a P/E ratio of -12.18 and a beta of 0.84.

CeriBell (NASDAQ:CBLL) last announced its earnings results on Monday, May 11th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.13). The business had revenue of $26.49 million during the quarter, compared to analyst estimates of $26.09 million. CeriBell had a negative return on equity of 38.19% and a negative net margin of 63.51%. As a group, analysts forecast that CeriBell, Inc. will post -1.69 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on CBLL. Weiss Ratings upgraded CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday. Canaccord Genuity Group reduced their price target on shares of CeriBell from $28.00 to $25.00 and set a “buy” rating on the stock in a research report on Tuesday, May 12th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, CeriBell has an average rating of “Moderate Buy” and an average price target of $22.20.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of CBLL. Vanguard Group Inc. lifted its holdings in CeriBell by 11.1% during the 3rd quarter. Vanguard Group Inc. now owns 1,473,856 shares of the company’s stock worth $16,935,000 after buying an additional 147,013 shares in the last quarter. KCM Capital Inc lifted its stake in shares of CeriBell by 40.0% during the first quarter. KCM Capital Inc now owns 1,400,000 shares of the company’s stock valued at $25,662,000 after acquiring an additional 400,000 shares during the period. Yu Fan lifted its stake in shares of CeriBell by 10.7% during the second quarter. Yu Fan now owns 1,353,166 shares of the company’s stock valued at $25,345,000 after acquiring an additional 130,964 shares during the period. Bank of New York Mellon Corp boosted its holdings in CeriBell by 1,945.9% in the fourth quarter. Bank of New York Mellon Corp now owns 1,221,927 shares of the company’s stock valued at $26,797,000 after acquiring an additional 1,162,200 shares during the last quarter. Finally, Novo Holdings A S increased its position in CeriBell by 2.3% in the second quarter. Novo Holdings A S now owns 900,000 shares of the company’s stock worth $16,857,000 after purchasing an additional 20,000 shares during the period.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.